Kornimate/medical-research-clean huggingface dataset:
the efficacy of oral motor therapy in children with autism

Conditions: Autism

Summary: children with autism spectrum disorders have speech disorders, which in turn aggravate communication difficulties and lead to an increase in their core symptoms. this experiment attempts to investigate the efficacy of chinese language oral motor therapy in improving various aspects of articulation, language ability, and behavior of children with autism in conjunction with the international general autism scale, and provides a basis for the rational formulation of clinical treatment plans.

oral motor therapy (omt) is a treatment process that uses tactile and proprioceptive stimulation techniques to promote the normalization of the sensory perception of the mouth (jaw, lips, tongue), suppress abnormal mouth movement patterns, and establish normal mouth movement patterns, following the principles of motor skill development. this study investigates the efficacy of chinese language oral motor therapy on improving various aspects of articulation, language ability, and behavior of children with autism. the study is divided into two parts, each eight weeks long. eighty subjects who met the inclusion/exclusion criteria were randomly divided into 2 groups: the experimental group and the control group, in a 1:1 ratio. the experimental group was treated with 2 months of aba+oral motor therapy followed by 2 months of aba therapy; the control group was treated with 2 months of aba therapy followed by 2 months of aba+oral motor therapy. each subject underwent abc, cars, s-s, vb-mapp, and ablls-r assessments before enrollment, 2 months after enrollment, and after discharge from the group.

Eligibility criteria:
inclusion criteria: 1. children who meet the dsm-v diagnosis of autism. 2. age 2-5 years old, regardless of gender. 3. native chinese language. 4. no prior oral motor therapy. 5. family members voluntarily participated in this study and signed an informed consent form. exclusion criteria: 1. children with co-occurring epilepsy. 2. children with comorbid other psychiatric disorders. 3. children with severe hearing impairment, history of visual impairment/blindness, organic disease of the mouth/throat, or significant medical illness or condition that prevents the child from participating in treatment procedures. 4. children who received other oral motor training or speech articulation therapy during the intervention period. 5. those who could not perform the intervention as planned after participating in the experiment. 6. those deemed unsuitable by the investigator to participate in this experiment.
internet-based self-help program for vestibular rehabilitation in chronic dizziness

Conditions: Vertigo

Summary: chronic dizziness,or persistent positional perceptual dizziness (ppps) is a common condition that results in impaired quality of life and work ability of those affected. vestibular rehabilitation (vr) is an evidence-based and recommended treatment for chronic dizziness. the treatment involves training in specific exercises that challenge the balance system and eventually improve dizziness. the main challenge with this treatment is that it is usually best provided with individual follow-up of therapists trained in the method. limited resources and the lack of dissemination of this knowledge mean that only a minority of patients receive adequate treatment. an internet-based self-help program in vestibular rehabilitation has been developed in norwegian with demonstration and instructions of exercises. the program has six lessons, together lasting for six weeks. patients are given the opportunity to exercise at home, without the use of treatment resources and without spending time traveling to the treatment site. patients will have access through their general practitioner or health institution at no extra cost. if it turns out that the program works according to the intention, the investigators will be able to offer vr to a large number of ppps patients who previously would not receive treatment for their condition. the aim of the pilot study is to find out if the internet program for ppps works as intended and evaluate incoming data and make changes to the program. in addition, the investigators will gain experience in using the program before designing a randomized clinical trial (rct). the aim of such an rct would be to compare this internet based treatment to traditional treatment.


Eligibility criteria:
inclusion criteria: * satisfy diagnostic criteria for persistent positional perceptual dizziness (ppps) or satisfy criteria with a duration of \<3 months * vertigo symptom scale (vss-sf) \>12 exclusion criteria: * cognitive dysfunction that is so pronounced that it will make participation difficult * unable to read, understand norwegian * severe medical or psychiatric illness (including substance abuse) that reduces the patient's ability to follow the vr program

Keywords: rehabilitation telerehabilitation internet norway
training executive, attention and motor skills (teams): preliminary studies

Conditions: Attention Deficit Hyperactivity Disorder

Summary: training executive, attention and motor skills (teams) is a new research program for preschool children with attention-deficit/hyperactivity disorder (adhd) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). these activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about adhd symptoms and associated impairments.


Eligibility criteria:
inclusion criteria: 1. be at least 4.0 and less than 6.0 years of age; 2. receive a t-score on the hyperactivity scale of the behavior assessment system for children, second edition (basc-2) of at least 65 (1.5 sd above the mean) by either teacher or parent rating, and a score of at least 60 (1 sd above the mean) by the other rater; 3. meet diagnostic criteria for adhd-c or adhd-hi as ascertained using the kiddie-sads, which will be administered to the parent. exclusion criteria: 1. chronic medical illness or is taking systemic medication; 2. diagnosed neurological disorder; 3. full scale iq below 80 as measured by the stanford-binet - fifth edition abbreviated battery; 4. diagnosis of autism, pervasive developmental disorder or post-traumatic stress disorder; 5. determined to be physically aggressive with other children; 6. parent enrolled in a parent management training program; 7. not attending school or day

Keywords: adhd executive function preschool children treatment memory attention training cognitive enhancement
different cycles of neoadjuvant pd-1 blockades + chemotherapy for advanced gastric cancer

Conditions: Gastric Adenocarcinoma

Summary: the goal of this observational study is to analyze the impact of different durations of neoadjuvant pd-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. the main questions it aims to answer are: * does the duration of neoadjuvant treatment influence tumor regression grading (trg)? * how does treatment duration affect perioperative safety and clinical outcomes? participants who have previously undergone neoadjuvant pd-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.


Eligibility criteria:
inclusion criteria: * non-bedridden patients aged 18-90 years; * histologically confirmed gastric or gastroesophageal junction adenocarcinoma by biopsy; * evaluated as resectable advanced gastric cancer via ct, mri, or laparoscopic exploration; * no prior anti-tumor treatments such as chemotherapy, radiotherapy, or immunotherapy; * no history of other malignancies within the past 5 years; * received at least one cycle of pd-1 inhibitor combined with chemotherapy preoperatively, with no restrictions on the specific pd-1 inhibitor or chemotherapeutic agents; * underwent radical gastrectomy after neoadjuvant therapy; * no severe underlying diseases. exclusion criteria: * incomplete or inaccessible clinical and pathological data; * postoperative pathology confirming non-gastric or non-gastroesophageal junction adenocarcinoma; * distant metastases present prior to treatment; * concurrent diagnosis of other malignancies.

Keywords: advanced gastric adenocarcinoma neoadjuvant immunotherapy chemotherapy cycles
a study to evaluate the incrediwear products immediately after acl repair

Conditions: Anterior Cruciate Ligament Tear; Medial Collateral Ligament

Summary: to assess the benefits of using the incrediwear knee products after acl or acl+mcl arthroscopic surgery, on the postoperative pain, range of motion and effusion. the study team will compare patients with incrediwear products, or placebo incrediwear products, or no products during the first 6-month postoperative period. the group that does not wear the incrediwear or placebo products is considered the standard of care control group and will proceed with the normal standard of care compression hose.

after knee surgery, the participant will be randomly assigned to one of the three groups. the participant will have a 1-in-3 chance of being assigned to each group. the products will be placed on the participant by the hospital staff according to the random assignment sent with the surgical packet. study screening/pre-operative appointment * the surgeon confirms the participant meets the inclusion criteria and are scheduled for surgery in the next few weeks, and how the participant may be eligible to participate in the study. * the surgeon will discuss the study and possible risks/benefits of being in the research. • day of surgery * the study packet will be sent to the hospital by the clinical staff. the packet will include a study number assignment, the products assigned the study number, and the patient study journal. the participant, surgeon, and hospital staff will not know which group the participant are in, with the exception of the standard of care control group, as this group will wear the hospital-issued compression hose. • postoperative recovery * subjective: patient rates surgical site pain, on a 0-10 vas pain scale. patients will record pain medication type and quantity taken in a daily pain diary. * objective: surgical extremity range of motion, and surgical extremity knee effusion, measured by either the physical therapist or the surgeon at the postop appointment. * measurements will be taken at; preop appointment, postop day 0, day 3, day 7, day 14, day 21, day 30 (1 month), day 45, day 60 (2 month), day 100 (3 month), and day 180 (6 month).

Eligibility criteria:
inclusion criteria: * consented to protocol * compliant protocol * bmi less than 35 * undergoing acl or acl+mcl within 30 days exclusion criteria: * pregnancy * rheumatoid arthritis * poorly controlled diabetes (hga1c \> 7.5) * previous blood clots * bmi greater than 35 * varicosities on operative leg * pain management patient * prior knee surgery to the operative / study knee * worker's comp patients

Keywords: anterior cruciate ligament tear medial collateral ligament tear anterior cruciate ligament repair medial collateral ligament repair arthroscopic surgery
delayed cerebral ischaemia and coagulation alterations after aneurysmal subarachnoid haemorrhage

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: despite the advances in neurosurgical and -radiological techniques and intensive care, the mortality and morbidity rates in sah have not changed in recent years. there is still only a limited understanding of the mechanisms of secondary insults causing brain injury after sah, also called delayed cerebral ischemia (dci). in this study, the investigators are exploring the use of quantifiable biomarkers from blood and continuous eeg monitoring as tools for the diagnostics of dci. additionally, the investigators are looking into other clinical variables (eg. pain, heart function) as factors of dci.

subarachnoidal hemorrhage (sah) is a cause of long-term disability and death. annually about 1000 people in finland suffer from sah, their average age being under 50 years. sah has a mortality rate of 12 % acutely and 40 % of patients die within a month from admission to hospital. in addition, 30 % of the surviving patients remain with neurological deficits. most survivors of the primary insult suffer from a secondary injury during the first 2-3 weeks from the insult. despite the advances in neurosurgical and -radiological techniques and intensive care, the mortality and morbidity rates in sah have not changed in recent years. there is still only a limited understanding of the mechanisms of secondary insults causing brain injury after sah, also called delayed cerebral ischemia (dci). in this study, the investigators are exploring the use of quantifiable biomarkers from blood and continuous eeg monitoring as tools for the diagnostics of dci. additionally, the investigators are looking into other clinical variables (eg. pain, heart function) as factors of dci.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * admitted to the tampere university hospital icu due to aneurysmal sah * acute subarachnoid haemorrhage (confirmed by computed tomography, ct, and confirmed origin either with computed angiography (cta) or digital subtraction angiography (dsa) * definite or approximated time for the onset of symptoms and delay to icu admission no more than 24 hours * expected treatment time at least 120 hours in the tampere university hospital exclusion criteria: * known pregnancy * any long-term anticoagulant or antithrombotic medication, except for low-dose aspirin (under 150 mg/day) * known active cancer or cirrhotic liver disease or end-stage renal disease requiring renal replacement therapy

Keywords: aneurysmal subarachnoid hemorrhage delayed cerebral ischemia intensive care unit neurosurgery
study on effect of intestinal microbiota transplantation in hepatitis b virus induced cirrhosis

Conditions: Cirrhosis, Liver

Summary: chronic hepatitis b (chb) is a common infectious disease affecting up to 2 billion people worldwide. around 650 thousand people died of liver failure, cirrhosis and primary liver cancer caused by chronic hepatitis b every year. 3%-5% compensatory liver cirrhosis develop to decompensated cirrhosis and suffer from series symptoms such as fatigue, edema, portal hypertension, splenomegaly, hemorrhage, hepatic encephalopathy, hepatorenal syndrome and so on. chronic hepatitis b is closely related to the imbalance of intestinal microbiota, and the intestinal microbiota of patients is significantly different from healthy people. the response of patients to hepatitis b virus can be influenced by reconstructing intestinal flora, while intestinal microbiota transplantation(imt) is a significant method to achieve it. in a previous study using imt to treat hbeag positive chronic hepatitis b patients combined with antiviral therapy, 80% of them has reached hbeag clearance. the investigators propose a randomized trial of imt in patients with hbv induced cirrhosis. patients will be randomized to either control group or imt group over a 12 months period.

a group of 60 patients with hbv induced cirrhosis will be recruited for study, which involved a 4 times imt with gastroduodenoscopy and the time interval is generally 2 weeks. participants can keep taking their present treatment. all participants will be assessed at baseline, after 3 months, 6 months, 12 months from baseline in order to evaluate the possible changes in: (1)imaging changes: color doppler ultrasound of portal vein, ct/mri, fibroscan score of liver fibrosis and steatosis, grading of varicosity under gastroscopy(gi); (2)basic information and symptoms; (3)biochemical indexes: liver function, four items of liver fiber, lipid metabolism, blood routine, coagulation function, blood ammonia, inflammation, oxidative stress, urine routine; sugar metabolism indicators (blood glucose, glycosylated hemoglobin, insulin level and insulin resistance level). (4) changes of gut microbiota: the changes of gut microbiota will be assessed by high-throughput sequencing (16s rrna) on baseline, 3 months, 6 months and 12 months after treatment samples to assess changes associated with imt.

Eligibility criteria:
inclusion criteria: * written informed consent/assent as appropriate, able to keep treatment * 18 to 50 years of age * chronic hepatitis b, definitely diagnosed as hepatic fibrosis/cirrhosis through fibroscan/biopsy of liver biopsy exclusion criteria: * drug treatment(immunosuppressive drugs, biological agents, high dose vitamins or other immunosuppressive drugs * other immune related diseases * gastrointestinal organic lesions such as gastroesophageal reflux disease, inflammatory bowel disease, intestinal tumor * medical or social condition which in the opinion of the principal investigator would interfere with or prevent regular follow up * participating in other clinical trials

Keywords: hbv induced cirrhosis intestinal microbiota transplantation microbiota
bioequivalence study of pf-06651600 capsules relative to tablets and estimation of food effect on capsules.

Conditions: Healthy Participants

Summary: the study will be conducted as a phase 1, open-label, single-dose, randomized, 2- or 3 period, cross over design in a single cohort.


Eligibility criteria:
inclusion criteria: * male and female participants who are healthy as determined by medical evaluation including a detailed medical history, complete physical examination, which includes bp and pulse rate measurement, clinical laboratory tests, and cardiac evaluation (including ecg). * bmi of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine (including diabetes), pulmonary, gastrointestinal, cardiovascular (including hypertension and congestive heart failure), hepatic, psychiatric, neurological, dermatological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy). * known immunodeficiency disorder, including positive serology for human immunodeficiency virus (hiv) at screening, or a first degree relative with a hereditary immunodeficiency. participants with any of the following acute or chronic infections or infection history: * any infection requiring treatment within 2 weeks prior to the dosing visit. * any infection requiring hospitalization or parenteral antimicrobial therapy within 60 days of the first dose of study intervention. * any infection judged to be an opportunistic infection or clinically significant by the investigator, within the past 6 months of the first dose of study intervention. * known active or history of recurrent bacterial, viral, fungal, mycobacterial or other infections. * history of recurrent (more than one episode of) localized dermatomal herpes zoster, or history of disseminated (single episode) herpes simplex or disseminated herpes zoster.
evaluation of different surgical approaches used for conservative management of placenta accreta spectrum in sohag university hospital

Conditions: Placenta Accreta Spectrum

Summary: the objective of this study is to evaluate different intra-operative procedures to control bleeding in cases of pas disorders aiming to determine the best procedure regarding maternal morbidity and mortality post-operatively, and to evaluate the long-term effects of conservative management of pas disorders.

the term "placenta accreta spectrum" (pas), formerly known as "morbidly adherent placenta" or "abnormally invasive placenta," refers to the aberrant trophoblast invasion of all or a portion of the placenta into the myometrium of the uterus. according to the depth of the villous invasion into the myometrium, the spectrum is assorted into three groups: placenta accreta (villi attach to the myometrium without invading it), placenta increta (villi infiltrate the myometrium), and placenta percreta (villi pierce through the uterine serosa and may infiltrate the surrounding tissues). the optimal strategy for managing pas disorders remains debatable. conservative management of pas disorders includes all techniques aimed at preserving the uterus. because intraoperative bleeding from pas disorders is frequently massive and dramatic, causing severe maternal morbidity and mortality, it is essential to have a well-planned, effective, and rapid approach to this surgical challenge.

Eligibility criteria:
inclusion criteria: * women with at least one previous caesarean section and suspected pas disorders by imaging studies exclusion criteria: * patients with intraoperative spontaneous placental separation. * patients with a preoperative diagnosis of placenta percreta who chose to have an elective hysterectomy. * any other associated uterine pathology requiring hysterectomy. * coagulation disorders.
phase iii randomized, double-blind, placebo-controlled study of guanfacine for tourette syndrome and attention deficit hyperactivity disorder

Conditions: Tourette Syndrome

Summary: objectives: i. evaluate the safety and efficacy of the alpha-2 adrenergic agonist guanfacine in children and adolescents with tourette syndrome or other chronic tic disorder, and attention deficit hyperactivity disorder.

protocol outline: this is a randomized, double-blind study. patients are stratified by pubertal status. there is a 7- to 14-day washout with a placebo prior to treatment for all patients. the first group receives oral guanfacine 3 times a day for 8 weeks. the dose is gradually increased to minimize sedation; by day 14, most patients are stabilized and the dose is then increased as clinically indicated and tolerated. the second group receives a placebo 3 times a day for 8 weeks. patients in either group may be treated with guanfacine for an additional 8 weeks.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * tourette syndrome or other chronic tic disorder meeting diagnostic and statistical manual of mental disorders-iv (dsm-iv) criteria * dsm-iv diagnosis of attention deficit hyperactivity disorder (adhd) clinician's global impression for adhd greater than 4 hyperactivity index of conners parent or teacher questionnaire standard score 65 or higher (1.5 standard deviation units) --prior/concurrent therapy-- * at least 2 weeks since medication for tics, adhd, or obsessive compulsive disorder (4 weeks since neuroleptics or fluoxetine) * no failure on prior guanfacine --patient characteristics-- * hepatic: no liver failure * renal: no renal failure * cardiovascular: no hypertension no other heart disease * pulmonary: no pulmonary disease * other: no intelligence quotient below 80 no current dsm-iv diagnosis of the following: major depression bipolar disorder pervasive developmental disorder psychotic disorder no seizure disorder no other significant medical condition no pregnant women

Keywords: tourette syndrome neurologic and psychiatric disorders rare disease